Omentin-1, visfatin and adiponectin levels in relation to bone mineral density in Iranian postmenopausal women

Bone

Volumn 51, Issue 5, 2012, Pages 876-881

  Tohidi, Maasumeh ^a   Akbarzadeh, Samad ^a   Larijani, Bagher ^b   Kalantarhormozi, Mohammadreza ^a   Ostovar, Afshin ^a   Assadi, Majid ^a   Vahdat, Katayoun ^a   Farrokhnia, Maryam ^a   Sanjdideh, Zahra ^a   Amirinejad, Roya ^a   Nabipour, Iraj ^a  

^a BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adipocytokine; Adiponectin; Adipose tissue; Menopause; Omentin 1; Visfatin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMENTIN 1; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DENSITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IRAN; NORMAL HUMAN; POSTMENOPAUSE; PROTEIN BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ADIPONECTIN; AGED; AGED, 80 AND OVER; BONE DENSITY; CYTOKINES; FEMALE; GPI-LINKED PROTEINS; HUMANS; IRAN; LECTINS; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE;

EID: 84865827673     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.08.117     Document Type: Article

References (50)

1. Zaidi M., Buettner C., Sun L., Iqbal J. Minireview: the link between fat and bone: does mass beget mass?. Endocrinology 2012, 153:2070-2075.
2. Magni P., Dozio E., Galliera E., Ruscica M., Corsi M.M. Molecular aspects of adipokine-bone interactions. Curr Mol Med 2010, 10:522-532.
3. Scherer P.E., Williams S., Fogliano M., Baldini G., Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270:26746-26749.
4. Jurimae J., Rembel K., Jurimae T., Rehand M. Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res 2005, 37:297-302.
5. Dietz J.J., Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 2003, 148:293-300.
6. Chandran M., Phillips S.A., Ciaraldi T., Henry R.R. Adiponectin: more than just another fat cell hormone?. Diabetes Care 2003, 26:2442-2450.
7. Luo X.H., Guo L.J., Xie H., Yuan L.Q., Wu X.P., Zhou H.D., et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 2006, 21:1648-1656.
8. Hida K., Wada J., Eguchi J., Zhang H., Baba M., Seida A., et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005, 102:10610-10615.
9. Eriksson J., Franssila-Kallunki A., Ekstrand A., Saloranta C., Widen Schalin C., et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989, 321:337-343.
10. Sonoli S.S., Shivprasad S., Prasad C.V., Patil A.B., Desai P.B., Somannavar M.S. Visfatin-a review. Eur Rev Med Pharmacol Sci 2011, 15:9-14.
11. Li Y., He X., Li Y., He J., Anderstam B., Andersson G., et al. Nicotinamide phosphoribosyltransferase (Nampt) affects the lineage fate determination of mesenchymal stem cells: a possible cause for reduced osteogenesis and increased adipogenesis in older individuals. J Bone Miner Res 2011, 26:2656-2664.
12. Schaffler A., Neumeier M., Herfarth H., Furst A., Scholmerich J., Buchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005, 1732:96-102.
13. Yang R.Z., Lee M.J., Hu H., Pray J., Wu H.B., Hansen B.C., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:E1253-E1261.
14. Tan B.K., Adya R., Farhatullah S., Lewandowski K.C., O'Hare P., Lehnert H., et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008, 57:801-808.
15. de Souza Batista C.M., Yang R.Z., Lee M.J., Glynn N.M., Yu D.Z., Pray J., et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655-1661.
16. Xie H., Xie P.L., Luo X.H., Wu X.P., Zhou H.D., Tang S.Y., et al. Omentin-1 exerts bone-sparing effect in ovariectomized mice. Osteoporos Int 2012, 23:1425-1436.
17. Richards J.B., Valdes A.M., Burling K., Perks U.C., Spector T.D. Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab 2007, 92:1517-1523.
18. Jurimae J., Jurimae T. Plasma adiponectin concentration in healthy pre- and postmenopausal women: relationship with body composition, bone mineral, and metabolic variables. Am J Physiol Endocrinol Metab 2007, 293:E42-E47.
19. Wu N., Wang Q.P., Li H., Wu X.P., Sun Z.Q., Luo X.H. Relationships between serum adiponectin, leptin concentrations and bone mineral density, and bone biochemical markers in Chinese women. Clin Chim Acta 2010, 411:771-775.
20. Assadi M., Salimipour H., Akbarzadeh S., Nemati R., Jafari S.M., Bargahi A., et al. Correlation of circulating omentin-1 with bone mineral density in multiple sclerosis: the crosstalk between bone and adipose tissue. PLoS One 2011, 6:e24240.
21. Guo L.J., Jiang T.J., Liao L., Liu H., He H.B. Relationship between serum omentin-1 level and bone mineral density in girls with anorexia nervosa. J Endocrinol Invest Jun 18 2012, [Epub ahead of print].
22. Nabipour I., Larijani B., Beigi S., Jafari S.M., Amiri M., Assadi M., et al. Relationship among insulinlike growth factor I concentrations, bone mineral density, and biochemical markers of bone turnover in postmenopausal women: a population-based study. Menopause 2008, 15:934-939.
23. Liu R., Wang X., Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract 2011, 93:21-25. Diabetes Res Clin Pract.
24. Kazama K., Usui T., Okada M., Hara Y., Yamawaki H. Omentin plays an anti-inflammatory role through inhibition of TNF-alpha-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 2012, 686:116-123. Eur J Pharmacol.
25. Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull 2011, 34:307-310.
26. Duan X.Y., Xie P.L., Ma Y.L., Tang S.Y. Omentin inhibits osteoblastic differentiation of calcifying vascular smooth muscle cells through the PI3K/Akt pathway. Amino Acids 2011, 41:1223-1231.
27. Yoo H.J., Hwang S.Y., Hong H.C., Choi H.Y., Yang S.J., Seo J.A., et al. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol 2011, 10:103.
28. van't Hof R.J., Ralston S.H. Nitric oxide and bone. Immunology 2001, 103:255-261.
29. Wimalawansa S.J. Nitric oxide: novel therapy for osteoporosis. Expert Opin Pharmacother 2008, 9:3025-3044.
30. Maruyama S., Shibata R., Kikuchi R., Izumiya Y., Rokutanda T., Araki S., et al. Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism. J Biol Chem 2012, 287:408-417.
31. Kanazawa I. Dose Adiponectin have adverse effects on bone mass and fracture?. Internal Med: Open Access 1:e101. doi:10.4172/ime.1000e101.
32. Samelson E.J., Broe K.E., Demissie S., Beck T.J., Karasik D., Kathiresan S., et al. Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip. J Clin Endocrinol Metab 2008, 93:1789-1795.
33. Saddi-Rosa P., Oliveira C.S., Giuffrida F.M., Reis A.F. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2010, 2:21.
34. Stephens J.M., Vidal-Puig A.J. An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opin Lipidol 2006, 17:128-131.
35. Akbarzadeh S., Nabipour I., Jafari S.M., Movahed A., Motamed N., Assadi M., et al. Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2012, 95:132-138.
36. Brown J.E., Onyango D.J., Ramanjaneya M., Conner A.C., Patel S.T., Dunmore S.J., et al. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells. J Mol Endocrinol 2010, 44:171-178.
37. Revollo J.R., Kor̈ rner A., Mills K.F., Satoh A., Wang T., Garten A., et al. Nampt/PBEF/visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007, 6:363-375.
38. Moschen A.R., Geiger S., Gerner R., Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat Res 2010, 690:95-101.
39. Sucunza N., Barahona M.J., Resmini E., Fernández-Real J.M., Ricart W., Farrerons J., et al. A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. J Clin Endocrinol Metab 2009, 94:3889-3896.
40. Gruodyte R., Jurimae J., Cicchella A., Stefanelli C., Passariello C., Jürimäe T. Adipocytokines and bone mineral density in adolescent female athletes. Acta Paediatr 2010, 99:1879-1884.
41. Peng X.D., Xie H., Zhao Q., Wu X.P., Sun Z.Q., Liao E.Y. Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta 2008, 387:31-35.
42. Zhang H., Xie H., Zhao Q., Xie G.Q., Wu X.P., Liao E.Y., et al. Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in post-menopausal Chinese women. J Endocrinol Invest 2010, 33:707-711.
43. Luo X.H., Guo L.J., Yuan L.Q., Xie H., Zhou H.D., Wu X.P., et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 2005, 309:99-109.
44. Ealey K.N., Kaludjerovic J., Archer M.C., Ward W.E. Adiponectin is a negative regulator of bone mineral and bone strength in growing mice. Exp Biol Med (Maywood) 2008, 233:1546-1553.
45. Napoli N., Pedone C., Pozzilli P., Lauretani F., Ferrucci L., Incalzi R.A. Adiponectin and bone mass density: the InCHIANTI study. Bone 2010, 47:1001-1005.
46. Jurimae J., Kums T., Jurimae T. Adipocytokine and gherlin levels in relation to bone mineral density in physically active older women: longitudinal associations. Eur J Endocrinol 2009, 160:381-385.
47. Araneta M.R., von Muhlen D., Barrett-Connor E. Sex differences in the association between adiponectin and BMD, bone loss, and fractures: the Rancho Bernardo study. J Bone Miner Res 2009, 24:2016-2022.
48. Biver E., Salliot C., Combescure C., Gossec L., Hardouin P., Legroux-Gerot I., et al. Influence of adipokines and gherlin on bone mineral density and fracture risk: a systematic review and met-analysis. J Clin Endocrinol Metab 2011, 96:2703-2713.
49. Sodi R., Hazell M.J., Durham B.H., Rees C., Ranganath L.R., Fraser W.D. The circulating concentration and ratio of total and high molecular weight adiponectin in post-menopausal women with and without osteoporosis and its association with body mass index and biochemical markers of bone metabolism. Clin Biochem 2009, 42:1375-1380.
50. Finucane M.M., Stevens G.A., Cowan M.J., Danaei G., Lin J.K., Paciorek C.J., et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1million participants. Lancet 2011, 377:557-567.